Bioloom (Seed)
Funding Details
Date Award
September 30, 2023
Vertical
Biotech
Funding URL
View Funding Page
Premoney Valuation
$1,000,000
Valuation
$15,000,000
Funding Amount
$2,500,000
Company Info
Founding Year
2019
Traction
Bioloom has successfully completed preclinical studies and is preparing for Phase 1 clinical trials. The company has garnered significant interest from key opinion leaders in the autoimmune disease space and has established collaborations with leading academic institutions.
Organizations Involved
SOSV, Y Combinator, Stanford University
Founders
Alice Chen, David Lee
Market
Healthcare
Location
San Francisco, CA, US
Coinvestors
SOSV, Y Combinator
Company Description

Bioloom is a biotech company specializing in developing novel therapeutics for autoimmune diseases by leveraging its proprietary platform that combines machine learning algorithms with high-throughput screening technologies. The company's approach enables the rapid identification of potential drug candidates with high efficacy and low toxicity, offering a promising solution for patients suffering from autoimmune disorders.

Links
Website
Back to HomeBack to Biotech DealsView Funding Announcement